Clinical-stage biotechnology
What if humanity's worst diseases are caused by a virus already within us?
What if we have a cure?
8% of the human genome is ancient viral code — human endogenous retroviruses (HERVs) dormant for millennia. HERVs enabled us to grow our human brain in the first place. But, when HERV proteins are activated at the wrong time, they may cause ALS, Multiple Sclerosis, Schizophrenia and other forms of Psychosis, memory loss, Type 1 Diabetes, and other devastating conditions. GeNeuro is in the clinic with the first drugs to systematically target HERV reactivation with patented, biomarker-targeted, monoclonal antibodies.More than $150 million in government funding has been invested to bring our science to patients and to produce groundbreaking results in phase 2 clinical trials targeting multiple sclerosis, Type I diabetes, Covid Brain Fog, and soon ALS. We have developed laboratory tests that can detect the HERV proteins and identify patients who might benefit from treatment. We are partnered with the US National Institutes of Health and leading universities. Now we aim to move to phase 3, while also treating our first patients under compassionate care in licensed jurisdictions. GeNeuro is a daughter company of NRx Pharmaceuticals, Inc. (Nasdaq:NRXP)
The GeNeuro Hypothesis
The HERV Hypothesis
Human endogenous retroviruses are remnants of ancient viral infections that became permanently integrated into our ancestors' genomes. Under certain conditions, these sequences reactivate — producing proteins that trigger neuroinflammation, immune dysregulation, and neurodegeneration. GeNeuro's platform targets these proteins with precision antibodies.
Learn the science→Disease focus
Targeting HERV-driven pathology
Multiple Sclerosis
Phase IIHERV-W Env
HERV-W envelope protein drives microglial activation and myelin destruction in MS patients. Phase II results demonstrate a statistically significant reduction in T1 Black Holes — areas of permanent brain necrosis visible on MRI — at 24 months compared to placebo.
ALS
Entering Phase I/IIHERV-K Env
HERV-K envelope protein is demonstrated to cause motor neuron degeneration in animal subjects and in human motor neurons in culture. Under a Cooperative Research and Development Agreement with the NIH/NINDS, GeNeuro's antibody GNK-301 was shown to prevent motor neuron degeneration in mouse brains and human brain cells in culture.
Psychosis
Phase IHERV-W Env
Elevated HERV-W Env expression is found in the brains of schizophrenia and first-episode psychosis patients, linked to neuroinflammatory pathways.
Long Covid — Brain Fog
Phase IIHERV-W Env
SARS-CoV-2 infection is a known HERV-W reactivation trigger. Phase II results demonstrate a statistically significant reduction in memory alterations with temelimab compared to placebo, directly linking HERV-W neuroinflammation to the cognitive impairment at the core of Long Covid Brain Fog.
Type 1 Diabetes
Phase IIHERV-W Env
HERV-W Env protein triggers autoimmune destruction of pancreatic beta cells. Phase II results demonstrate a statistically significant reduction in pancreatic islet cell death compared to placebo.
Clinical pipeline
From hypothesis to clinical evidence
| Program | Target | Indication | Stage | Status |
|---|---|---|---|---|
| GNbAC1 (temelimab) | HERV-W Env | Multiple Sclerosis | Phase II | Active |
| GNbAC1 | HERV-W Env | Psychosis | Phase I | Completed |
| GNK-301 | HERV-K Env | ALS | Entering Phase I/II | Active |
| GNbAC1 | HERV-W Env | Type 1 Diabetes | Phase II | Completed |
| GNbAC1 (temelimab) | HERV-W Env | Long Covid — Brain Fog | Phase II | Completed |
By the numbers
Partner with us to redefine disease
GeNeuro is actively seeking strategic partnerships with pharmaceutical companies, academic institutions, and investors who share our conviction that HERV biology represents the next frontier in medicine.